Fig. 2: Discovery of a pan-marburgvirus antibody.

a, Schematic of the immunization schedule used to discover MARV GP-directed monoclonal antibodies (n = 4 mice). b, Dose–response neutralization curves for MARV16, MR78 and MR191 against VSV pseudotyped with the MARV/Musoke GP. Data are the mean ± s.e.m. from three technical replicates. Data are representative of 3–5 additional biological replicates. c, Neutralization potency of MARV16, MR78, MR191 and 4C2, a MERS-CoV antibody, against authentic MARV/Musoke. Data points reflect PRNT₅₀ values obtained from two biological replicates using distinct batches of IgGs. The black line indicates the mean PRNT₅₀ value. d, Binding affinity of the MARV16 Fab to immobilized MARV GPΔMuc_WT measured using BLI. e,f, MARV16, MR78 and MR191 IgG (e) or Fab (f) binding to immobilized MARV GPΔMuc_WT assessed by BLI. g, MARV16 IgG binding to immobilized MARV GPΔMuc_WT at variable pH values using BLI. h, Schematic highlighting GP mutations (black vertical lines) in MARV variants relative to MARV/Musoke. Residue numbers correspond to the MARV/Musoke GP. i, Neutralization potency of MARV16, MR78 and MR191 against VSV pseudotyped with the indicated MARV GP. j, Phylogenetic tree constructed using the amino acid sequences of related filovirus GPs with sequence identity relative to the MARV/Musoke GP shown to the right. k, Neutralization potency of MARV16, MR78, MR191 and EBOV-515 against VSV pseudotyped with the indicated filovirus GP. Data presented in i and k are averaged IC₅₀ values obtained from at least two biological replicates conducted in technical triplicate using distinct batches of IgG and pseudoviruses. l–o, MARV GPΔMuc_WT, EBOV GPΔMuc, SUDV GPΔMuc, thermolysin-cleaved EBOV GPΔMuc or thermolysin-cleaved SUDV GPΔMuc binding to immobilized EBOV-515 (l), MR191 (m), MR78 (n) or MARV16 (o) IgGs assessed with BLI. Data presented in d–g and l–o reflect one biological replicate and are representative of two biological replicates using distinct batches of proteins.